Repros Therapeutics volatility up into positive top-line results for Androxal Repros Therapeutics overall option implied of 150 is above its 26-week average of 79 according to Track Data, suggesting larger price movement into the reported top-line results for the first pivotal study of Androxal, ZA-301, in the treatment of secondary hypogonadism.
News For RPRX From The Last 14 Days
Check below for free stories on RPRX the last two weeks.
Repros needed unique Androxal label even before ADCOM panel, says Ladenburg Ladenburg said that given the FDA advisory committee's 20 to 1 vote that it believes the FDA will likely revise testosterone replacement therapy labels to restrict their use in hypogonadal patients with clear etiology. However, Ladenburg added that Repros was always going to have to establish a unique label for Androxal and the firm believes that the company's ongoing and completed trials will provide sufficient data for filing and approval by the FDA in secondary hypogonadism. The firm maintains its Buy rating and $35 price target on Repros.
Repros Therapeutics sell-off overdone, says Brean Capital Brean Capital said the selling in Repros Therapeutics is overdone after an FDA panel voted overwhelmingly in support for a more restrictive label that limits the use of TRT drugs to only patients with classic hypogonadism. The firm feels since Androxal has not been targeting age-related hypogonadism it does not deserve to be negatively impacted by yesterday's ruling. Brean Capital maintains its Buy rating on Repros Therapeutics and $41 price target on the shares.